This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy
In this edition of NephJC, we discuss the largest case series of kidney biopsies in patients with Diabetes.
This week we will discuss whether a bundled, team-based hypertension intervention- featuring intensive BP targets, home monitoring, health coaching, and audit feedback- can overcome poverty, clinical inertia, and fragmented care to improve blood pressure control in low-income patients receiving care at federally qualified health centers.
This week, we will discuss a phase 2 trial of the TRPC6 inhibitor BI 764198 in FSGS—an early signal for a podocyte-targeted therapy showing proteinuria reduction but set against small numbers, heterogeneity, and methodological trade-offs that frame this as direction-finding rather than definitive evidence.
Fresh from the #ERA26 Late-Breaking Clinical Trials, the MAJESTY study compared obinutuzumab with tacrolimus and raises important questions about the future of anti-CD20 therapy.
👑 Is deeper B-cell depletion enough to claim the throne?
📖 Check out the latest Visual Abstract by Dr Divya Bajpai
Recién llegado desde #ERA26, el estudio MAJESTY comparó obinutuzumab frente a tacrolimus y plantea importantes interrogantes sobre el futuro de las terapias anti-CD20 en la nefropatía membranosa primaria.
👑 ¿Será suficiente una depleción más profunda de células B para reclamar el trono?
📖 Revisa el más reciente resumen visual elaborado por la Dra Divya Bajpai
¿Hemos subestimado la frecuencia de la nefrópatía no diabética (NND) en pacientes diabeticos? Una cohorte basada en biopsias renales de 49,075 pacientes refuerza cuán heterogénea puede ser la NND y destaca las características clínicas más asociadas con la NND. ¿A quién debemos biopsiar? ¿Cuándo debemos sospecharla? ¿Cómo puede la histología cambiar el pronóstico?
Acompáñanos este martes en la discusión de #NephJC.
Have we been underestimating NDKD in patients with diabetes? A biopsy-based cohort of 49,075 patients reinforces just how heterogeneous kidney disease can be in DN and highlights the clinical features most strongly associated with NDKD. So, who should we biopsy? When should we suspect NDKD? And how can histology change prognosis?
Join us for this tuesday on the #NephJC discussion
This week we will discuss whether a bundled, team-based hypertension intervention- featuring intensive BP targets, home monitoring, health coaching, and audit feedback- can overcome poverty, clinical inertia, and fragmented care to improve blood pressure control in low-income patients receiving care at federally qualified health centers.
Can multifaceted strategies improve hypertension control in low-income patients?
Hypertension remains one of the leading cardiovascular risk factors worldwide. However, achieving adequate blood pressure control continues to be a major challenge, especially in low-income populations. The IMPACTS-BP trial has arrived, a study evaluating whether a multifaceted team-based strategy can improve blood pressure control and adherence to antihypertensive therapy.
Check out the VA by Dra Akshaya Jayachandran, and don’t forget to join the live discussion with @NephJC on X and Bluesky
¿Puede el trabajo colaborativo mejorar el control de la hipertensión?
La hipertensión arterial continúa siendo uno de los principales factores de riesgo cardiovascular a nivel mundial. Sin embargo, lograr un adecuado control de la presión arterial sigue siendo un desafío, especialmente en poblaciones de bajos ingresos. Hoy aterriza el ensayo IMPACTS-BP, un estudio que evaluó si una estrategia multifacética basada en equipos puede mejorar el control y la adherencia al tratamiento antihipertensivo.
Revisa el resumen visual realizado por la Dra Akshaya Jayachandran y no olvides unirte en vivo con @NephJC en X y Bluesky
This week, we will discuss a phase 2 trial of the TRPC6 inhibitor BI 764198 in FSGS—an early signal for a podocyte-targeted therapy showing proteinuria reduction but set against small numbers, heterogeneity, and methodological trade-offs that frame this as direction-finding rather than definitive evidence.
Por primera vez, una terapia dirigida al podocito muestra eficacia clínica en GEFyS. Esta semana #NephJC revisa el ECA fase 2 de BI 764198, inhibidor oral de TRPC6, que redujo proteinuria, estabilizó el FGe y fue bien tolerado. ¿El inicio de una nueva era en GEFyS? Revisa el resumen visual por la Dra Divya Bajpai
For the first time, a podocyte-targeted therapy shows clinical efficacy in FSGS. This week #NephJC covers the phase 2 RCT of BI 764198, an oral TRPC6 inhibitor that lowered proteinuria, preserved eGFR, and was well tolerated. A new era in FSGS? Check out the visual abstract by Divya Bajpai
This week, we will discuss why a large registry cohort was needed to move past decades of scattered case reports and clarify the true risk of hydralazine‑associated vasculitis. When rare events hide in noise, only scale can reveal the signal. Can population‑level data finally bring this paradox into focus?
A large registry cohort was essential to move beyond scattered case reports and finally quantify the true risk of hydralazine‑associated vasculitis. When rare events blur into background noise, only scale can clarify the signal. Can population‑level data sharpen the picture?
Check out Divya Bajpai VA
Un gran registro poblacional era esencial para superar décadas de reportes aislados y cuantificar por fin el riesgo real de la vasculitis asociada a hidralazina. Cuando los eventos raros se confunden con el ruido de fondo, solo la escala permite distinguir la señal. ¿Puede la evidencia a nivel poblacional aclarar por fin este panorama?
Revisa el resumen visual por Divya Bajpai , traducir por Milagros Flores
